There is an increasing body of evidence demonstrating that growth factor networks are highly interactive with oestrogen receptor (ER) signalling in the control of breast cancer growth. As such, tumour responses to anti- hormones are likely to be a composite of the ER and growth factor inhibitory activity of these agents. The current article examines the modulation of growth factor networks during endocrine response, and presents in vitro and clinical evidence that epidermal growth factor receptor signalling, maintained in either an ER-dependent or -independent manner, is critical to anti- hormonal-resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor, ZD 1839 (Iressa; AstraZeneca) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.

This article has been cited by other articles:

				B. P. Gomez, R. B. Riggins, A. N. Shajahan, U. Klimach, A. Wang, A. C. Crawford, Y. Zhu, A. Zwart, M. Wang, and R. Clarke Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines FASEB J, December 1, 2007; 21(14): 4013 - 4027. [Abstract] [Full Text] [PDF]

				R. J. Pietras and D. C. Marquez-Garban Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers Clin. Cancer Res., August 15, 2007; 13(16): 4672 - 4676. [Full Text] [PDF]

				C. M. Silva and M. A. Shupnik Integration of Steroid and Growth Factor Pathways in Breast Cancer: Focus on Signal Transducers and Activators of Transcription and Their Potential Role in Resistance Mol. Endocrinol., July 1, 2007; 21(7): 1499 - 1512. [Abstract] [Full Text] [PDF]

				C. Catania, T. M. De Pas, G. Pelosi, M. Manzotti, L. Adamoli, F. Nole, and A. Goldhirsch Erlotinib-Induced Breast Cancer Regression Ann. Pharmacother., November 1, 2006; 40(11): 2043 - 2047. [Abstract] [Full Text] [PDF]

				R. M. O'Regan, C. Osipo, E. Ariazi, E. S. Lee, K. Meeke, C. Morris, A. Bertucci, M. A.B. Sarker, R. Grigg, and V. C. Jordan Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin. Cancer Res., April 1, 2006; 12(7): 2255 - 2263. [Abstract] [Full Text] [PDF]

				I. Shin, T. Miller, and C. L. Arteaga ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors Clin. Cancer Res., February 1, 2006; 12(3): 1008s - 1012s. [Abstract] [Full Text] [PDF]

				J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, V. Guillem, S. Gonzalez, S. Sauleda, I. Marimon, J. M. Tabernero, et al. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer J. Clin. Oncol., August 10, 2005; 23(23): 5323 - 5333. [Abstract] [Full Text] [PDF]

				S. Tovey, B. Dunne, C. J. Witton, A. Forsyth, T. G. Cooke, and J. M.S. Bartlett Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? Clin. Cancer Res., July 1, 2005; 11(13): 4835 - 4842. [Abstract] [Full Text] [PDF]

				R I Nicholson, I R Hutcheson, S E Hiscox, J M Knowlden, M Giles, D Barrow, and J M W Gee Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S29 - S36. [Abstract] [Full Text] [PDF]

				L.-A. Martin, I. Farmer, S. R D Johnston, S. Ali, and M. Dowsett Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S75 - S84. [Abstract] [Full Text] [PDF]

				H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson Development of strategies for the use of anti-growth factor treatments Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182. [Abstract] [Full Text] [PDF]

				J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]

				W. Pao and V. A. Miller Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions J. Clin. Oncol., April 10, 2005; 23(11): 2556 - 2568. [Abstract] [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]

				J A Vendrell, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, and P A Cohen Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines Endocr. Relat. Cancer, March 1, 2005; 12(1): 75 - 92. [Abstract] [Full Text] [PDF]

				R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy Endocr. Relat. Cancer, December 1, 2004; 11(4): 623 - 641. [Abstract] [Full Text] [PDF]

				A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]

				H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814. [Abstract] [Full Text] [PDF]

				S. Guo and G. E. Sonenshein Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mol. Cell. Biol., October 1, 2004; 24(19): 8681 - 8690. [Abstract] [Full Text] [PDF]

				J. Shou, S. Massarweh, C. K. Osborne, A. E. Wakeling, S. Ali, H. Weiss, and R. Schiff Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer J Natl Cancer Inst, June 16, 2004; 96(12): 926 - 935. [Abstract] [Full Text] [PDF]

				M. Ellis Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition Oncologist, June 3, 2004; 9(suppl_3): 20 - 26. [Abstract] [Full Text] [PDF]

				R. I. Nicholson, I. R. Hutcheson, J. M. Knowlden, H. E. Jones, M. E. Harper, N. Jordan, S. E. Hiscox, D. Barrow, and J. M. W. Gee Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination Clin. Cancer Res., January 1, 2004; 10(1): 346S - 354S. [Abstract] [Full Text] [PDF]

				J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro Endocrinology, November 1, 2003; 144(11): 5105 - 5117. [Abstract] [Full Text] [PDF]

				M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al. Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status Cancer Res., October 1, 2003; 63(19): 6523 - 6531. [Abstract] [Full Text] [PDF]

				G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]

				J. S. Carroll, D. K. Lynch, A. Swarbrick, J.-M. Renoir, B. Sarcevic, R. J. Daly, E. A. Musgrove, and R. L. Sutherland p27Kip1 Induces Quiescence and Growth Factor Insensitivity in Tamoxifen-treated Breast Cancer Cells Cancer Res., August 1, 2003; 63(15): 4322 - 4326. [Abstract] [Full Text] [PDF]

				F. M. Sirotnak, Y. She, F. Lee, J. Chen, and H. I. Scher Studies with CWR22 Xenografts in Nude Mice Suggest That ZD1839 May Have a Role in the Treatment of Both Androgen-dependent and Androgen-independent Human Prostate Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3870 - 3876. [Abstract] [Full Text] [PDF]

				M. Ranson ZD1839 (IressaTM): For More Than Just Non-Small Cell Lung Cancer Oncologist, August 15, 2002; 7(90004): 16 - 24. [Abstract] [Full Text] [PDF]

				C. L. Arteaga Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? Oncologist, August 15, 2002; 7(90004): 31 - 39. [Abstract] [Full Text] [PDF]